Free Trial

Oppenheimer's Rating of Retension Pharmaceuticals on 11/3/2026

On November 3, 2026, Oppenheimer updated its outlook on Retension Pharmaceuticals (NASDAQ:RTSN) with the action "Initiated Coverage", setting a "Outperform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Oppenheimer Holdings, Inc.

DateCompanyAction
11/13/2026
Wolverine World Wide, Inc. stock logo
WWW
Wolverine World Wide
Downgrade
11/13/2026
Corteva, Inc. stock logo
CTVA
Corteva
Downgrade
11/13/2026
CorMedix Inc stock logo
CRMD
CorMedix
Reiterated Rating
11/13/2026
Enersys stock logo
ENS
Enersys
Lower Price Target
11/13/2026
Forgent Power Solutions, Inc. stock logo
FPS
Forgent Power Solutions
Lower Price Target
11/13/2026
Enovix Corporation stock logo
ENVX
Enovix
Downgrade
More Ratings From Oppenheimer Holdings, Inc.